@entity1313 are currently diagnosed on the basis of their histology. The most common types in adults are @entity816 , @entity3271 and @entity816 or mixed @entity5 , which almost invariably lead to death. Improvements in outcome have been elusive despite intensive research. Recent findings indicate that response to conventional therapy, at least in some cases, correlates better with genetic characteristics than histopathology. An understanding of the molecular mechanisms that underlie the malignant phenotype of @entity11 also provides the possibility of rational design of molecularly targeted therapies. This approach has proved successful in other areas of oncology. As many @entity5 have the same types of @entity74 , molecular targeted therapies developed for nonbrain @entity5 types might be adapted for the treatment of @entity1313 . There are a number of unique problems involved in treating @entity5 in the brain that must be overcome. The genetic predictors of response to conventional therapies, the genes and cellular mechanisms involved in @entity11 development, and potential therapeutic targets are reviewed. The possibility of designing tailored molecular therapy based on the molecular characteristics of the @entity5 is also explored.

Mechanisms of disease: genetic predictors of response to treatment in XXXX .

@entity1313 :: ('MESH:D001932', 'Disease') :: ['Brain tumors', 'brain tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity11 :: ('MESH:D005910', 'Disease') :: ['glioma', 'gliomas'] @entity816 :: ('MESH:D001254', 'Disease') :: ['oligoastrocytomas', 'astrocytomas'] @entity74 :: ('MESH:D030342', 'Disease') :: ['molecular abnormalities'] @entity3271 :: ('MESH:D009837', 'Disease') :: ['oligodendrogliomas']
@entity1313 :: (MESH:D001932,Disease) :: ['brain tumors']
